Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A head-to-head clinical phase 1b trial of the APG777 in combination with APG990 (APG279 program) against Dupixent in moderate-to-severe AD of APG279

Next Previous
Trial Profile

A head-to-head clinical phase 1b trial of the APG777 in combination with APG990 (APG279 program) against Dupixent in moderate-to-severe AD of APG279

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs APG-279 (Primary) ; Dupilumab
  • Indications Atopic dermatitis
  • Focus Adverse reactions

Most Recent Events

  • 11 Aug 2025 According to an Apogee Therapeutics media release, first patient dosed in phase 1b head-to-head trial of APG279 versus DUPIXENT in atopic dermatitis, with readout expected in 2H 2026.
  • 11 Aug 2025 Status changed to recruiting.
  • 03 Mar 2025 According to an Apogee Therapeutics media release, data expected in the second half of 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top